Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2)

Survey of Ophthalmology

Volumn 58, Issue 6, 2013, Pages 536-559

  Wu, Lihteh ^a   Evans, Teodoro ^a   Arevalo, J Fernando ^b  

^a Instituto de Cirugia Ocular   (Costa Rica)

^b Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

Choroidal neovascularization; Idiopathic juxtafoveal telangiectasis; Juxtafoveal retinal telangiectasia; Lutein; Macular edema; Macular pigment; Macular telangiectasia (Mac Tel 2); M ller cells; Parafoveal telangiectasis; Perifoveal telangiectasis; Retinal angiomatous proliferation; Retinal telangiectasis; Subretinal neovascularization; Zeaxanthin

Indexed keywords

ANECORTAVE; ATM PROTEIN; BEVACIZUMAB; CORTICOSTEROID; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN;

ATAXIA TELANGIECTASIA MUTATED GENE; CAUSAL ATTRIBUTION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONFOCAL BLUE REFLECTANCE IMAGING; DEGENERATIVE DISEASE; DEMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; EPIGENETICS; EYE SURGERY; FLUORESCENCE ANGIOGRAPHY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC JUXTAFOVEAL RETINAL TELANGIECTASIS TYPE 2A; LASER COAGULATION; MEDICAL HISTORY; MICROPERIMETRY; MUELLER CELL; OPHTHALMOSCOPY; PERIMETRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA EDEMA; RETINAL TELANGIECTASIA; REVIEW; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBMACULAR SURGERY; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; VISUAL ACUITY;

CHOROIDAL NEOVASCULARIZATION; IDIOPATHIC JUXTAFOVEAL TELANGIECTASIS; JUXTAFOVEAL RETINAL TELANGIECTASIA; LUTEIN; MACULAR EDEMA; MACULAR PIGMENT; MACULAR TELANGIECTASIA (MAC TEL 2); MÜLLER CELLS; PARAFOVEAL TELANGIECTASIS; PERIFOVEAL TELANGIECTASIS; RETINAL ANGIOMATOUS PROLIFERATION; RETINAL TELANGIECTASIS; SUBRETINAL NEOVASCULARIZATION; ZEAXANTHIN;

CAPILLARY PERMEABILITY; CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR EDEMA; RETINAL NEOVASCULARIZATION; RETINAL TELANGIECTASIS; RETINAL VESSELS;

EID: 84886283227     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2012.11.007     Document Type: Review

References (222)

1. Abujamra S., Bonanomi M.T., Cresta F.B., et al. Idiopathic juxtafoveolar retinal telangiectasis: clinical pattern in 19 cases. Ophthalmologica 2000, 214:406-411.
2. Adamis A.P., Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005, 25:111-118.
3. Albini T.A., Benz M.S., Coffee R.E., et al. Optical coherence tomography of idiopathic juxtafoveolar telangiectasia. Ophthalmic Surg Lasers Imaging 2006, 37:120-128.
4. Alldredge C.D., Garretson B.R. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003, 23:113-116.
5. Arevalo J.F., Sanchez J.G., Garcia R.A., et al. Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007, 245:1673-1680.
6. Aung K.Z., Wickremasinghe S.S., Makeyeva G., et al. The prevalence estimates of macular telangiectasia type 2: the Melbourne Collaborative Cohort Study. Retina 2010, 30:473-478.
7. Bakke E.F., Drolsum L. Iris microhaemangiomas and idiopathic juxtafoveolar retinal telangiectasis. Acta Ophthalmol Scand 2006, 84:818-822.
8. Barbazetto I.A., Room M., Yannuzzi N.A., et al. ATM gene variants in patients with idiopathic perifoveal telangiectasia. Invest Ophthalmol Vis Sci 2008, 49:3806-3811.
9. Barthelmes D., Gillies M.C., Fleischhauer J.C., et al. Acase of idiopathic perifoveal Telangiectasia preceded by features of cone dystrophy. Eye (Lond) 2007, 21:1534-1535.
10. Barthelmes D., Sutter F.K., Gillies M.C. Differential optical densities of intraretinal spaces. Invest Ophthalmol Vis Sci 2008, 49:3529-3534.
11. Baumuller S., Charbel Issa P., Scholl H.P., et al. Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. Ophthalmology 2010, 117:2162-2168.
12. Berger A.S., McCuen B.W., Brown G.C., et al. Surgical removal of subfoveal neovascularization in idiopathicjuxtafoveolar retinal telangiectasis. Retina 1997, 17:94-98.
13. Bernstein P.S., Balashov N.A., Tsong E.D., et al. Retinal tubulin binds macular carotenoids. Invest Ophthalmol Vis Sci 1997, 38:167-175.
14. Bhosale P., Larson A.J., Frederick J.M., et al. Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye. JBiol Chem 2004, 279:49447-49454.
15. Bhosale P., Li B., Sharifzadeh M., et al. Purification and partial characterization of a lutein-binding protein from human retina. Biochemistry 2009, 48:4798-4807.
16. Blaauwgeers H.G., Holtkamp G.M., Rutten H., et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999, 155:421-428.
17. Bone R.A., Landrum J.T., Friedes L.M., et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res 1997, 64:211-218.
18. Bottoni F., Eandi C.M., Pedenovi S., et al. Integrated clinical evaluation of Type 2A idiopathic juxtafoveolar retinal telangiectasis. Retina 2010, 30:317-326.
19. Bringmann A., Pannicke T., Grosche J., et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res 2006, 25:397-424.
20. Cahill M., O'Keefe M., Acheson R., et al. Classification of the spectrum of Coats' disease as subtypes of idiopathic retinal telangiectasis with exudation. Acta Ophthalmol Scand 2001, 79:596-602.
21. Cakir M., Kapran Z., Basar D., et al. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol 2006, 16:711-717.
22. Campbell F.P. Coats' disease and congenital vascularretinopathy. Trans Am Ophthalmol Soc 1976, 74:365-424.
23. Campo R.V., Reeser F.H. Retinal telangiectasia secondary to bilateral carotid artery occlusion. Arch Ophthalmol 1983, 101:1211-1213.
24. Canny C.L., Oliver G.L. Fluorescein angiographic findings in familial exudative vitreoretinopathy. Arch Ophthalmol 1976, 94:1114-1120.
25. Cantarella G., Lempereur L., Presta M., et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis invitro and invivo. Faseb J 2002, 16:1307-1309.
26. Carmeliet P., Tessier-Lavigne M. Common mechanisms ofnerve and blood vessel wiring. Nature 2005, 436:193-200.
27. Casswell A.G., Chaine G., Rush P., et al. Paramacular telangiectasis. Trans Ophthalmol Soc UK 1986, 105(Pt 6):683-692.
28. Charbel Issa P., Berendschot T.T., Staurenghi G., et al. Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 2008, 49:1172-1177.
29. Charbel Issa P., Finger R.P., Helb H.M., et al. Anew diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol 2008, 86:464-465.
30. Charbel Issa P., Finger R.P., Holz F.G., et al. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2008, 92:941-945.
31. Charbel Issa P., Finger R.P., Kruse K., et al. Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study. Am J Ophthalmol 2011, 151:876-886.
32. Charbel Issa P., Helb H.M., Holz F.G., et al. Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol 2008, 145:169-175.
33. Charbel Issa P., Helb H.M., Rohrschneider K., et al. Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 2007, 48:3788-3795.
34. Charbel Issa P., Holz F.G., Scholl H.P. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007, 114:1736-1742.
35. Charbel Issa P., Holz F.G., Scholl H.P. Metamorphopsia in patients with macular telangiectasia type 2. Doc Ophthalmol 2009, 119:133-140.
36. Charbel Issa P., Scholl H.P., Gaudric A., et al. Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. Eye (Lond) 2009, 23:435-441.
37. Charbel Issa P., Troeger E., Finger R., et al. Structure-function correlation of the human central retina. PLoS One 2010, 5:e12864.
38. Charbel Issa P., van der Veen R.L., Stijfs A., et al. Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp Eye Res 2009, 89:25-31.
39. Chen C., Wu L., Wu D., et al. The local cone and rod system function in early age-related macular degeneration. Doc Ophthalmol 2004, 109:1-8.
40. Chew E., Gillies M., Bird A. Macular telangiectasia: a simplified classification. Arch Ophthalmol 2006, 124:573-574.
41. Chew E.Y., Murphy R.P., Newsome D.A., et al. Parafoveal telangiectasis and diabetic retinopathy. Arch Ophthalmol 1986, 104:71-75.
42. Chopdar A. Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. Br J Ophthalmol 1978, 62:243-250.
43. Chuang E.L., Sharp D.M., Fitzke F.W., et al. Retinal dysfunctionin central serous retinopathy. Eye (Lond) 1987, 1(Pt 1):120-125.
44. Clark A.F. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 2007, 52(Suppl 1):S26-S34.
45. Clemons T.E., Gillies M.C., Chew E.Y., et al. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (Mac Tel) Project. Invest Ophthalmol Vis Sci 2008, 49:4340-4346.
46. Clemons T.E., Gillies M.C., Chew E.Y., et al. Baseline characteristics of participants in the natural history study of macular telangiectasia (Mac Tel) Mac Tel Project Report No. 2. Ophthalmic Epidemiol 2010, 17:66-73.
47. Clevidence B.A., Bieri J.G. Association of carotenoids with human plasma lipoproteins. Methods Enzymol 1993, 214:33-46.
48. Coats G. Forms of retinal disease with massive exudation. RLondon Ophthalmol Hosp Rep 1908, 17:440-459.
49. Coats G. Über Retinitis exsudativa (Retinitis haemorrhagica externa). Graefes Arch Clin Exp Ophthalmol 1912, 81:275-327.
50. Cohen S.M., Cohen M.L., El-Jabali F., et al. Optical coherence tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis. Retina 2007, 27:59-66.
51. Costa R.A., Scapucin L., Moraes N.S., et al. Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res 2002, 25:287-297.
52. Curcio C.A. Photoreceptor topography in ageing and age-related maculopathy. Eye (Lond) 2001, 15:376-383.
53. Curcio C.A., Millican C.L., Allen K.A., et al. Aging of the human photoreceptor mosaic: evidence for selective vulnerability of rods in central retina. Invest Ophthalmol Vis Sci 1993, 34:3278-3296.
54. Davidorf F.H., Pressman M.D., Chambers R.B. Juxtafoveal telangiectasis-a name change?. Retina 2004, 24:474-478.
55. De Lahitte G.D., Cohen S.Y., Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol 2004, 138:892-894.
56. Delori F.C., Goger D.G., Hammond B.R., et al. Macular pigment density measured by autofluorescence spectrometry: comparison with reflectometry and heterochromatic flicker photometry. JOpt Soc Am A Opt Image Sci Vis 2001, 18:1212-1230.
57. Diaz-Rodriguez E.J. [Group 2A idiopathic parafoveal telangiectasis]. Arch Soc Esp Oftalmol 2005, 80:541-545.
58. Dong W., Li N., Gao D., et al. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. JVasc Surg 2008, 48:709-714.
59. Dorrell M.I., Aguilar E., Jacobson R., et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. JClin Invest 2009, 119:611-623.
60. Drenser K., Sarraf D., Jain A., et al. Crystalline retinopathies. Surv Ophthalmol 2006, 51:535-549.
61. Eandi C.M., Ober M.D., Freund K.B., et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006, 26:780-785.
62. Edelman J.L., Lutz D., Castro M.R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005, 80:249-258.
63. Eliassi-Rad B., Green W.R. Histopathologic study of presumed parafoveal telangiectasis. Retina 1999, 19:332-335.
64. Engelbrecht N.E., Aaberg T.M., Sung J., et al. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 2002, 120:320-324.
65. Fallano K.A., Ibrahim M., Nguyen Q.D., et al. Progressive changes from idiopathic macular telangiectasia seen with spectral domain optical coherence tomography. Can J Ophthalmol 2010, 45:649-650.
66. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
67. Finger R.P., Charbel Issa P., Fimmers R., et al. Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci 2009, 50:1366-1370.
68. Franze K., Grosche J., Skatchkov S.N., et al. Muller cells are living optical fibers in the vertebrate retina. Proc Natl Acad Sci USA 2007, 104:8287-8292.
69. Friedman S.M., Mames R.N., Stewart M.W. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg 1993, 24:551-553.
70. Fuijkschot J., Cruysberg J.R., Willemsen M.A., et al. Subclinical changes in the juvenile crystalline macular dystrophy in Sjogren-Larsson syndrome detected by optical coherence tomography. Ophthalmology 2008, 115:870-875.
71. Gamulescu M.A., Walter A., Sachs H., et al. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008, 246:1189-1193.
72. Gass J.D. Afluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasis. Arch Ophthalmol 1968, 80:592-605.
73. Gass J.D. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment 1997, Mosby, St. Louis, MO, pp 504-12.
74. Gass J.D. Muller cell cone, an overlooked part of the anatomy of the fovea centralis: hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr retinoschisis. Arch Ophthalmol 1999, 117:821-823.
75. Gass J.D. Histopathologic study of presumed parafoveal telangiectasis. Retina 2000, 20:226-227.
76. Gass J.D. Chorioretinal anastomosis probably occurs infrequently in type 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2003, 121:1345-1346.
77. Gass J.D. Juxtafoveal telangiectasis-a name change?. Retina 2005, 25:234-236. author reply 236-7.
78. Gass J.D., Blodi B.A. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993, 100:1536-1546.
79. Gass J.D., Oyakawa R.T. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982, 100:769-780.
80. Gaudric A., Ducos de Lahitte G., Cohen S.Y., et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2006, 124:1410-1419.
81. Gillies M.C., Zhu M., Chew E., et al. Familial asymptomatic macular telangiectasia type 2. Ophthalmology 2009, 116:2422-2429.
82. Goldberg M.F., Custis P.H. Retinal and other manifestations of incontinentia pigmenti (Bloch-Sulzberger syndrome). Ophthalmology 1993, 100:1645-1654.
83. Green W.R., Quigley H.A., De la Cruz Z., et al. Parafoveal retinal telangiectasis. Light and electron microscopy studies. Trans Ophthalmol Soc UK 1980, 100:162-170.
84. Gregori N., Flynn H.W. Surgery for full-thickness macular hole in patients with idiopathic macular telangiectasia type 2. Ophthalmic Surg Lasers Imaging 2010, 41(Online):1-4.
85. Gualino V., Cohen S.Y., Delyfer M.N., et al. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 2005, 140:757-758.
86. Gupta V., Gupta A., Dogra M.R., et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging 2005, 36:482-486.
87. Gurwin E.B., Fitzsimons R.B., Sehmi K.S., et al. Retinal telangiectasis in facioscapulohumeral muscular dystrophywith deafness. Arch Ophthalmol 1985, 103:1695-1700.
88. Hannan S.R., Madhusudhana K.C., Rennie C., et al. Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins. Br J Ophthalmol 2007, 91:1729-1730.
89. Helb H.M., Charbel Issa P., VDV R.L., et al. Abnormal macular pigment distribution in type 2 idiopathic macular telangiectasia. Retina 2008, 28:808-816.
90. Hershberger V.S., Hutchins R.K., Laber P.W. Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging 2003, 34:318-320.
91. Hirano Y., Yasukawa T., Usui Y., et al. Indocyanine green angiography-guided laser photocoagulation combined with sub-Tenon's capsule injection of triamcinolone acetonide for idiopathic macular telangiectasia. Br J Ophthalmol 2010, 94:600-605.
92. Hua J., Guerin K.I., Chen J., et al. Resveratrol inhibits pathological retinal neovascularization in vldlr-/- mice. Invest Ophthalmol Vis Sci 2011, 52:2809-2816.
93. Huerva V., Sanchez M.C. Juxtafoveolar telangiectasis associated with CREST syndrome. Ocul Immunol Inflamm 2008, 16:195-197.
94. Hung L.M., Chen J.K., Huang S.S., et al. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000, 47:549-555.
95. Hussain N., Das T., Sumasri K., et al. Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis. Am J Ophthalmol 2005, 140:333-335.
96. Hutton W.L., Snyder W.B., Fuller D., et al. Focal parafoveal retinal telangiectasis. Arch Ophthalmol 1978, 96:1362-1367.
97. Isaacs T.W., McAllister I.L. Familial idiopathic juxtafoveolar retinal telangiectasis. Eye (Lond) 1996, 10(Pt 5):639-642.
98. Jackson G.R., Owsley C., Curcio C.A. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev 2002, 1:381-396.
99. Jonas J.B., Kreissig I., Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005, 24:587-611.
100. Jorge R., Costa R.A., Calucci D., et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 2007, 245:1045-1048.
101. Kaga S., Zhan L., Matsumoto M., et al. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. JMol Cell Cardiol 2005, 39:813-822.
102. Karagiannis D., Georgalas I., Ladas I., et al. Acase of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis. Clin Interv Aging 2009, 4:63-65.
103. Kim I., Ryan A.M., Rohan R., et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999, 40:2115-2121.
104. Klein R., Blodi B.A., Meuer S.M., et al. The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. Am J Ophthalmol 2010, 150:55-62.
105. Koizumi H., Cooney M.J., Leys A., et al. Centripetal retinal capillary proliferation in idiopathic parafoveolar telangiectasis. Br J Ophthalmol 2007, 91:1719-1720.
106. Koizumi H., Iida T., Maruko I. Morphologic features of group2A idiopathic juxtafoveolar retinal telangiectasis in three-dimensional optical coherence tomography. Am J Ophthalmol 2006, 142:340-343.
107. Koizumi H., Slakter J.S., Spaide R.F. Full-thickness macular hole formation in idiopathic parafoveal telangiectasis. Retina 2007, 27:473-476.
108. Konstantinidis L., Mantel I., Zografos L., et al. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2009, 247:1567-1569.
109. Kovach J.L., Rosenfeld P.J. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009, 29:27-32.
110. Lamoureux E., Maxwell R., Marella M., et al. The longitudinal impact of Macular Telangiectasia (Mac Tel) Type 2 on vision-related quality of life. Invest Ophthalmol Vis Sci 2011, 52:2520-2524.
111. Landa G., Rosen R.B. Anew vascular pattern for idiopathic juxtafoveal telangiectasia revealed by the retinal function imager. Ophthalmic Surg Lasers Imaging 2010, 41:413-417.
112. LaVail M.M., Unoki K., Yasumura D., et al. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci USA 1992, 89:11249-11253.
113. LaVail M.M., Yasumura D., Matthes M.T., et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 1998, 39:592-602.
114. Leber T. Ueber eine durch Vorkommen multipler Miliaraneurysmen charakterisierte Form von Retinaldegeneration. Albrecht von Graefes Arch Klin Ophthalmol 1912, 81:1-14.
115. Lee B.L. Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. Retina 1996, 16:344-346.
116. Lee H.C., Liu M., Ho A.C. Idiopathic juxtafoveal telangiectasis in association with celiac sprue. Arch Ophthalmol 2004, 122:411-413.
117. Lee S.T., Friedman S.M., Rubin M.L. Cystoid macular edema secondary to juxtafoveolar telangiectasis in Coats' disease. Ophthalmic Surg 1991, 22:218-221.
118. Liang J., Williams D.R., Miller D.T. Supernormal vision and high-resolution retinal imaging through adaptive optics. JOpt Soc Am A Opt Image Sci Vis 1997, 14:2884-2892.
119. Lim J.I., Bressler N.M. Atypical parafoveal telangiectasis with subsequent anterior and posterior segment neovascularization. Retina 1992, 12:351-354.
120. Lira R.P., Silva V.B., Cavalcanti T.M., et al. Intravitreous ranibizumab as treatment for macular telangiectasia type 2. Arch Ophthalmol 2010, 128:1075-1078.
121. Liu X., Li Y., Liu Y., et al. Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy. Am J Pathol 2010, 176:504-515.
122. Maberley D.A., Yannuzzi L.A., Gitter K., et al. Radiation exposure: a new risk factor for idiopathic perifoveal telangiectasis. Ophthalmology 1999, 106:2248-2252. discussion 2252-2253.
123. Maguluri S., Recchia C.C., Recchia F.M. Neurosensory macular detachment in group 2a juxtafoveolar telangiectasis and resolution following intravitreal triamcinolone. Retin Cases Brief Rep 2007, 1:20-21.
124. Maia Junior O.O., Bonanomi M.T., Takahashi W.Y., et al. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol 2007, 144:296-299.
125. Mainster M.A., Reichel E. Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins. Ophthalmic Surg Lasers 2000, 31:359-373.
126. Mandal S., Venkatesh P., Abbas Z., et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2007, 245:1825-1829.
127. Mansour A.M., Schachat A. Foveal avascular zone in idiopathic juxtafoveolar telangiectasia. Ophthalmologica 1993, 207:9-12.
128. Margalit E., Apte R.S., Sadda S.R. Idiopathic parafoveal telangiectasis associated with a foveal pseudovitelliform lesion. Br J Ophthalmol 2002, 86:1455-1456.
129. Martinez J.A. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 2003, 121:1658-1659.
130. Maruko I., Iida T., Sekiryu T., et al. Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry. Br J Ophthalmol 2008, 92:1488-1491.
131. Massamba N., Querques G., Lamory B., et al. Invivo evaluation of photoreceptor mosaic in type 2 idiopathic macular telangiectasia using adaptive optics. Acta Ophthalmol 2011, 89:e601-e603.
132. Matsumoto Y., Yuzawa M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 2010, 54:320-324.
133. Matt G., Sacu S., Ahlers C., et al. Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye (Lond) 2010, 24:1535-1541. quiz 1542.
134. Mavrakanas N., Mendrinos E., Pournaras C.J., et al. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. Acta Ophthalmol 2009, 87:930-932.
135. Menchini U., Virgili G., Bandello F., et al. Bilateral juxtafoveolar telangiectasis in monozygotic twins. Am J Ophthalmol 2000, 129:401-403.
136. Millay R.H., Klein M.L., Handelman I.L., et al. Abnormal glucose metabolism and parafoveal telangiectasia. Am J Ophthalmol 1986, 102:363-370.
137. Moisseiev J., Lewis H., Bartov E., et al. Superficial retinal refractile deposits in juxtafoveal telangiectasis. Am J Ophthalmol 1990, 109:604-605.
138. Moon S.J., Berger A.S., Tolentino M.J., et al. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmic Surg Lasers Imaging 2007, 38:164-166.
139. Nachiappan K., Shanmugam M.P. Treatment of CNVM secondary to idiopathic juxtafoveal retinal telangiectasis by transpupillary thermotherapy. Am J Ophthalmol 2005, 139:577-578. author reply 578.
140. National Diabetes Fact Sheet: General Information and Estimates on Diabetes in the United States, 2002. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services,2003.
141. Nelson D.A., Krupsky S., Pollack A., et al. Special report: Noninvasive multi-parameter functional optical imaging of the eye. Ophthalmic Surg Lasers Imaging 2005, 36:57-66.
142. Newman E., Reichenbach A. The Muller cell: a functional element of the retina. Trends Neurosci 1996, 19:307-312.
143. Nishijima K., Ng Y.S., Zhong L., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007, 171:53-67.
144. Nishikawa S., Tamai M. Muller cells in the human foveal region. Curr Eye Res 2001, 22:34-41.
145. Nishimura M., Taniguchi Y. Retinal vascular patterns in the macula and the perimacular area in premature and full-term infants. Ophthalmologica 1982, 185:147-157.
146. Ober R.R., Bird A.C., Hamilton A.M., et al. Autosomal dominant exudative vitreoretinopathy. Br J Ophthalmol 1980, 64:112-120.
147. Oh K.T., Park D.W. Bilateral juxtafoveal telangiectasis in a family. Retina 1999, 19:246-247.
148. Olson J.L., Mandava N. Macular hole formation associated with idiopathic parafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2006, 244:411-412.
149. Ooto S., Hangai M., Takayama K., et al. High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci 2011, 52:5541-5550.
150. Ooto S., Hangai M., Takayama K., et al. High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci 2011, 52:5541-5550.
151. Park D., Schatz H., McDonald H.R., et al. Fibrovascular tissue in bilateral juxtafoveal telangiectasis. Arch Ophthalmol 1996, 114:1092-1096.
152. Park D.W., Schatz H., McDonald H.R., et al. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997, 104:1838-1846.
153. Parmalee N.L., Schubert C., Merriam J.E., et al. Analysis of candidate genes for macular telangiectasia type 2. Mol Vis 2010, 16:2718-2726.
154. Parodi M.B., Iacono P., Ravalico G. Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2007, 245:612-615.
155. Patel B., Duvall J., Tullo A.B. Lamellar macular hole associated with idiopathic juxtafoveolar telangiectasia. Br J Ophthalmol 1988, 72:550-551.
156. Paunescu L.A., Ko T.H., Duker J.S., et al. Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology 2006, 113:48-57.
157. Potter M.J., Szabo S.M., Chan E.Y., et al. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 2002, 133:149-151.
158. Potter M.J., Szabo S.M., Sarraf D., et al. Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can J Ophthalmol 2006, 41:34-37.
159. Povazay B., Hofer B., Torti C., et al. Impact of enhanced resolution, speed and penetration on three-dimensional retinal optical coherence tomography. Opt Express 2009, 17:4134-4150.
160. Powner M.B., Gillies M.C., Tretiach M., et al. Perifoveal Muller cell depletion in a case of macular telangiectasia type 2. Ophthalmology 2010, 117:2407-2416.
161. Powner M.B., Scott A., Zhu M., et al. Basement membrane changes in capillaries of the ageing human retina. Br J Ophthalmol 2011, 95:1316-1322.
162. Putteman A., Toussaint D., Graff E., et al. [Idiopathic familial juxtafoveolar retinal telangiectasias]. Bull Soc Belge Ophtalmol 1984, 209:81-90.
163. Querques G., Coscas G., Soubrane G., et al. Type II idiopathic macular telangiectasia and soft confluent drusen. Eur J Ophthalmol 2010, 20:466-468.
164. Querques G., Delle Noci N. Juxtafoveal telangiectasias. Ophthalmology 2008, 115:1636. author reply 1636.
165. Querques G., Delle Noci N. Re: Optical coherence tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis. Retina 2008, 28:368-369. author reply 369-70.
166. Quiroz-Mercado H., Ustariz-Gonzalez O., Martinez-Castellanos M.A., et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol 2007, 22:109-125.
167. Rapkin J.S., Hirsh D.K., Curry S. Idiopathic juxtafoveal telangiectasia and positional visual disturbance. Retina 1998, 18:183-184.
168. Reese A.B. Telangiectasis of the retina and Coats' disease. Am J Ophthalmol 1956, 42:1-8.
169. Rishi P., Kothari A.R. Parafoveal telangiectasia (PFT) has been associated with changes in macular architecture and macular holes (lamellar and full thickness). Retina 2008, 28:184-185. author reply 185-6.
170. Rishi P., Rishi E., Shroff D. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia. Indian J Ophthalmol 2009, 57:241-242.
171. Roe R.H., Jumper J.M., Gualino V., et al. Retinal pigment epitheliopathy, macular telangiectasis, and intraretinal crystal deposits in HIV-positive patients receiving ritonavir. Retina 2011, 31:559-565.
172. Roller A.B., Folk J.C., Patel N.M., et al. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011, 31:1848-1855.
173. Ruys J., De Laey J.J., Vanderhaeghen Y., et al. Intravitreal bevacizumab (avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye (Lond) 2007, 21:1433-1434.
174. Ryan S.J. Retina 2006, Elsevier Mosby, Philadelphia, PA, pp 1409-15.
175. Saint-Geniez M., Maharaj A.S., Walshe T.E., et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 2008, 3:e3554.
176. Sallo F.B., Leung I., Chung M., et al. Retinal crystals in type 2 idiopathic macular telangiectasia. Ophthalmology 2011, 118:2461-2467.
177. Sanchez J.G., Garcia R.A., Wu L., et al. Optical coherence tomography characteristics of group 2A idiopathic parafoveal telangiectasis. Retina 2007, 27:1214-1220.
178. Sandhu S.S., Steel D.H. Comment on macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. Eye (Lond) 2010, 24:1119.
179. Schmidt-Erfurth U., Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000, 45:195-214.
180. Schmitz-Valckenberg S., Fan K., Nugent A., et al. Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. Arch Ophthalmol 2008, 126:330-335.
181. Schmitz-Valckenberg S., Holz F.G., Bird A.C., et al. Fundus autofluorescence imaging: review and perspectives. Retina 2008, 28:385-409.
182. Schmitz-Valckenberg S., Ong E.E., Rubin G.S., et al. Structural and functional changes over time in Mac Tel patients. Retina 2009, 29:1314-1320.
183. Shanmugam M.P., Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 2005, 53:61-63.
184. Shen W., Li S., Chung S.H., et al. Retinal vascular changes after glial disruption in rats. JNeurosci Res 2010, 88:1485-1499.
185. Shen W., Zhang J., Chung S.H., et al. Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature. Invest Ophthalmol Vis Sci 2011, 52:119-127.
186. Shukla D. Evolution and management of macular hole secondary to type 2 idiopathic macular telangiectasia. Eye (Lond) 2011, 25:532-533.
187. Shukla D., Singh J., Kolluru C.M., et al. Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am J Ophthalmol 2004, 138:147-149.
188. Siddiqui N., Fekrat S. Group 2A idiopathic juxtafoveolar retinal telangiectasia in monozygotic twins. Am J Ophthalmol 2005, 139:568-570.
189. Sieving P.A., Caruso R.C., Tao W., et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006, 103:3896-3901.
190. Small R.G. Coats' disease and muscular dystrophy. Trans Am Acad Ophthalmol Otolaryngol 1968, 72:225-231.
191. Smithen L.M., Spaide R.F. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004, 138:884-885.
192. Snodderly D.M., Auran J.D., Delori F.C. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci 1984, 25:674-685.
193. Snodderly D.M., Brown P.K., Delori F.C., et al. The macularpigment. I. Absorbance spectra, localization, anddiscrimination from other yellow pigments in primateretinas. Invest Ophthalmol Vis Sci 1984, 25:660-673.
194. Snodderly D.M., Handelman G.J., Adler A.J. Distribution of individual macular pigment carotenoids in central retina of macaque and squirrel monkeys. Invest Ophthalmol Vis Sci 1991, 32:268-279.
195. Snyers B., Verougstraete C., Postelmans L., et al. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 2004, 137:812-819.
196. Soheilian M., Tavallali A., Peyman G.A. Identification of intraretinal neovascularization by high-speed indocyanine green angiography in idiopathic perifoveal telangiectasia. Ophthalmic Surg Lasers Imaging 2007, 38:167-169.
197. Sommerburg O.G., Siems W.G., Hurst J.S., et al. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye Res 1999, 19:491-495.
198. Steven P., Klinger M., Hoerauf H. [Bilateral pigmented epi- and submacular membrane]. Klin Monbl Augenheilkd 2008, 225:240-242.
199. Stoffelns B.M., Schoepfer K., Kramann C. [Idiopathic macular telangiectasia-follow-up with and without laser photocoagulation]. Klin Monbl Augenheilkd 2010, 227:252-256.
200. Suchting S., Bicknell R., Eichmann A. Neuronal clues to vascular guidance. Exp Cell Res 2006, 312:668-675.
201. Surguch V., Gamulescu M.A., Gabel V.P. Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 2007, 245:783-788.
202. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006, 6:717-726.
203. Tao W., Wen R., Goddard M.B., et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002, 43:3292-3298.
204. Tikellis G., Gillies M.C., Guymer R.H., et al. Retinal vascular caliber and macular telangiectasia type 2. Ophthalmology 2009, 116:319-323.
205. Tout S., Chan-Ling T., Hollander H., et al. The role of Muller cells in the formation of the blood-retinal barrier. Neuroscience 1993, 55:291-301.
206. Trabucchi G., Brancato R., Pierro L., et al. Idiopathic juxtafoveolar retinal telangiectasis and pigment epithelial hyperplasia: an optical coherence tomographic study. Arch Ophthalmol 1999, 117:405-406.
207. Trieschmann M., van Kuijk F.J., Alexander R., et al. Macular pigment in the human retina: histological evaluation of localization and distribution. Eye (Lond) 2008, 22:132-137.
208. Tseng S.H., Lin S.M., Chen J.C., et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004, 10:2190-2202.
209. van der Veen R.L., Fuijkschot J., Willemsen M.A., et al. Patients with Sjogren-Larsson syndrome lack macular pigment. Ophthalmology 2010, 117:966-971.
210. Vianna R.N., Squeri G., Turquetti R., et al. Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis. Can J Ophthalmol 2008, 43:492-493.
211. von Hippel E. Uber eine sehr seltene Erkrankung der Netzhaut. Albrecht von Graefes Archiv für Ophthalmologie 1904, 59:83-86.
212. Watzke R.C., Klein M.L., Folk J.C., et al. Long-term juxtafoveal retinal telangiectasia. Retina 2005, 25:727-735.
213. Whitehead A.J., Mares J.A., Danis R.P. Macular pigment: a review of current knowledge. Arch Ophthalmol 2006, 124:1038-1045.
214. Wilson C.A., Berkowitz B.A., Sato Y., et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992, 110:1155-1159.
215. Wong W.T., Forooghian F., Majumdar Z., et al. Fundus autofluorescence in type 2 idiopathic macular telangiectasia:correlation with optical coherence tomography and microperimetry. Am J Ophthalmol 2009, 148:573-583.
216. Wu L., Evans T., Arevalo J.F., et al. Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia. Retina 2008, 28:314-319.
217. Yamada E. Some structural features of the fovea centralis in the human retina. Arch Ophthalmol 1969, 82:151-159.
218. Yannuzzi L.A., Bardal A.M., Freund K.B., et al. Idiopathic macular telangiectasia. Arch Ophthalmol 2006, 124:450-460.
219. Yemelyanov A.Y., Katz N.B., Bernstein P.S. Ligand-binding characterization of xanthophyll carotenoids to solubilized membrane proteins derived from human retina. Exp Eye Res 2001, 72:381-392.
220. Zeimer M.B., Kromer I., Spital G., et al. Macular telangiectasia: patterns of distribution of macular pigment and response to supplementation. Retina 2010, 30:1282-1293.
221. Zeimer M.B., Padge B., Heimes B., et al. Idiopathic macular telangiectasia type 2: distribution of macular pigment and functional investigations. Retina 2010, 30:586-595.
222. Zhang K., Hopkins J.J., Heier J.S., et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implantsfor treatment of geographic atrophy in age-relatedmacular degeneration. Proc Natl Acad Sci USA 2011, 108:6241-6245.